16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
- RxCUI
- 2700745
- RxNorm name
- 16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
- Display name
- 16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
- Full name
- 16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:12
UNII Substances#
No records found.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4 | Avzivi 400 MG in 16 ML Injection [PSN] · 16 ML bevacizumab-tnjn 25 MG/ML Injection [Avzivi] [SBD] · 16 ML Avzivi 25 MG/ML Injection [SY] · Avzivi 400 MG per 16 ML Injection [SY] | 4 | 4 | These highlights do not include all the information needed to use Avzivi safely and effectively. See full prescribing information for Avzivi. Avzivi ® (bevacizumab-tnjn) injection, for intravenous use Initial U.S. Approval: 2023 Avzivi (bevacizumab-tnjn) is biosimilar to AVASTIN ® (bevacizumab) | 20250930 |